By investigating 36,000 immunosuppressed people (transplant recipients, people with blood malignancies and rare autoimmune disease on immunosuppression), we aim to assess:
1. What proportion will have detectable SARS-CoV2 Ab after 3 vaccine doses (and now 4) (1/5)